



**Supplementary Table S1.** Pharmacotherapy of comorbidities in RPH participants ( $n = 29$ ).


Class of medication	$n$ (%)
Proton pump inhibitors	5 (17)
Antidepressant/antipsychotics	5 (17)
Thyroid substitution (levothyroxine)	4 (13)
Bronchodilator	2 (7)
ACE inhibitor/calcium channel blocker	2 (7%)
Statin	2 (7%)
Beta receptor blocker	1 (3%)
Methotrexate	1 (3%)

LEGEND: ACE, angiotensin-converting enzyme.

**Supplementary Table S2.** Blood glucose, insulin, and C-peptide concentration during 5-h OGTT in individuals with RPH at baseline and at follow-up.

Time (min)	Glucose (mmol/L)			$p$ -Value	Insulin (mU/L)				$p$ -Value	C-peptide (nmol/L)				$p$ -Value
	1.	Visit Up	Follow		1.	Visit Up	Follow	1.		Visit Up	Follow			
<b>0</b>	4.9 ± 0.5	4.7 ± 0.7	0.121	4.5 ± 3.2	4.4 ± 4.2	0.977	0.5 ± 0.1	0.5 ± 0.2	0.756					
<b>30</b>	7.2 ± 1.5	7.1 ± 2.0	0.822	39.7 ± 22.9	43.0 ± 17.6	0.614	2.0 ± 0.7	2.2 ± 0.6	0.262					
<b>60</b>	6.7 ± 2.5	6.5 ± 2.5	0.581	64.6 ± 30.5	52.6 ± 18.5	0.149	3.1 ± 0.9	2.9 ± 0.7	0.312					
<b>120</b>	5.0 ± 1.6	4.9 ± 1.7	0.847	47.4 ± 49.0	43.7 ± 26.0	0.743	2.6 ± 1.3	2.6 ± 1.0	0.978					
<b>180</b>	3.6 ± 1.1	3.3 ± 0.9	0.174	14.8 ± 14.0	13.5 ± 11.2	0.633	1.2 ± 0.8	1.1 ± 0.7	0.364					
<b>240</b>	<b>4.2 ± 0.5*</b>	<b>3.7 ± 0.7*</b>	<b>0.007*</b>	5.5 ± 5.5	5.8 ± 5.1	0.833	0.5 ± 0.3	0.5 ± 0.2	0.841					
<b>300</b>	<b>4.7 ± 0.3*</b>	<b>4.0 ± 0.6*</b>	<b>0.000*</b>	4.2 ± 4.0	3.7 ± 3.0	0.682	0.4 ± 0.2	0.4 ± 0.2	0.904					

Means ± standard deviations are presented. Statistically significant values are presented in bold with an asterisk.



**Supplementary Figure S1. Comparison of insulin concentration in subjects with RPH at baseline and follow-up vs. the healthy control group, showing no difference in any time point during 5-h OGTT.**

Legend: RPH: reactive postprandial hypoglycemia, OGTT: oral glucose tolerance test.